Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) – Drugs In Development, 2023’, provides an overview of the Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
- The report reviews pipeline therapeutics for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) therapeutics and enlists all their major and minor projects
- The report assesses Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
AbbVie IncAccutar Biotechnology Inc
Acerta Pharma BV
Achelois BioPharma Inc
Advenchen Laboratories LLC
Amgen Inc
Aptose Biosciences Inc
Ascentage Pharma Group International
AstraZeneca Plc
BeiGene Ltd
Bio-Path Holdings Inc
BioIntegrator
Boryung Pharmaceutical Co Ltd
Bristol-Myers Squibb Co
Carna Biosciences Inc
Cellectar Biosciences Inc
Celltrion Inc
Chengdu Hyperway Pharmaceutical Co Ltd
CSPC Pharmaceutical Group Ltd
Curis Inc
Dana-Farber Cancer Institute Inc
Eli Lilly and Co
Emmaus Life Sciences Inc
Evopoint Bioscience Co Ltd
F. Hoffmann-La Roche Ltd
GC Cell Corp
Gilead Sciences Inc
Guangdong East Sunshine Pharmaceutical Co Ltd
Guangzhou BeBetter Medicine Technology Co Ltd
Haisco Pharmaceutical Group Co Ltd
Hangzhou Hezheng Pharmaceutical Co Ltd
Hangzhou Minsheng Pharmaceutical Group Co Ltd
Hangzhou Sumgen Biotech Co Ltd
Huazhong University of Science & Technology
Hutchison MediPharma Ltd
iCell Gene Therapeutics LLC
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Incyte Corp
InnoCare Pharma Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Karyopharm Therapeutics Inc
KeyMed Biosciences Inc
Loxo Oncology Inc
Merck & Co Inc
Mustang Bio Inc
National Cancer Institute US
National Taiwan University Hospital
neoX Biotech (HK) Ltd
Newave Pharmaceutical Inc
Nkarta Inc
Nurix Therapeutics Inc
OncoVerity Inc
Qilu Pharmaceutical Co Ltd
Qilu Puget Sound Biotherapeutics Corp
Rhizen Pharmaceuticals SA
Sanofi
Shandong New Time Pharmaceutical Co Ltd
Shengke Pharmaceuticals (Jiangsu) Ltd
Swedish Orphan Biovitrum AB
SymBio Pharmaceuticals Ltd
Takeda Pharmaceutical Co Ltd
TG Therapeutics Inc
TransThera Sciences (Nanjing) Inc
Vivolux AB
Wuhan Bio-Raid Biotechnology Co Ltd
X4 Pharmaceuticals Inc
Xi'An Yufan Biotechnology Co Ltd
Xuzhou Medical University
Zhejiang Borui Biopharmaceutical Co Ltd
Zhejiang Longchuan Biomedical Technology Co Ltd
Zhejiang University School of Medicine Hospital 1
Zibo Baiji Changsheng Pharmaceutical Co Ltd